Quintiles today announced that the company has been awarded the Society for Clinical Research Sites’ (SCRS) 2013 Clinical Research Organization (CRO) Eagle Award. The award recognizes outstanding leadership, professionalism, integrity, passion and dedication and is voted on by the sites themselves.
“Quintiles recognizes the vital and important role our dedicated and highly skilled investigators and their site teams play in conducting clinical research aimed at developing new and better medicines,” said Lindy Jones, senior vice president, Integrated Site Services, Quintiles. “We are thrilled to receive the Eagle Award which recognizes that we understand and are dedicated to working closely with all of our investigative sites. We are especially pleased because we were chosen by the sites themselves.”
“We are delighted to present the Eagle Award to Quintiles,” said SCRS President Christine Pierre. The award reflects the opinions of more than 1,000 investigative sites across the globe. Quintiles’ integrity in consistently demonstrating their keen interest in partnering with sites landed them with this prestigious recognition.”
In selecting this year’s nominees, investigative sites registering for the Site Solutions Summit were asked to nominate the sponsor and CRO they believe best demonstrate partnership commitment. Criteria for selection included availability of qualified staff to support the sites, willingness to collaborate, protocol design and execution, financial consideration, and partnering with sites for future work. Finalists were those sponsors and CROs that ranked in the 75th percentile or greater of nominations received. Once the finalists were identified, voting was open to all sites globally.Of the participating sites, 60% were from North America, 23% from Europe, 7% from South America, 3% from Asia-Pacific, 3% from Sub Saharan Africa, and 4% from “other.” Those who participated in the survey were mostly investigators (35%), site directors (31%), and study coordinators (21%). About Quintiles Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com. About SCRS SCRS is a trade organization representing global clinical research sites representing sites in 22 countries. SCRS’ mission is to unify and amplify the voice of the global clinical research site community. SCRS has become an active partner in industry-wide dialogues focused on improving the clinical research enterprise among the many industry initiatives. Sites, as well as companies that sponsor or support the work conducted at the clinical research sites, will benefit from membership. Visit www.myscrs.org. Click here to subscribe to Mobile Alerts for Quintiles.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV